Rescue treatment with tocilizumab for takayasu arteritis resistant to TNF-α blockers

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL. 70, 2012, Pages

  Salvarani, C ^a   Magnani, L ^a   Catanoso, M ^a   Pipitone, N ^a   Versari, A ^a   Dardani, L ^a   Pulsatelli, L ^b   Meliconi, R ^b   Boiardi, L ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Inhibitors; Interleukin 6; Takayasu arteritis; TNF ; Tocilizumab

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TOCILIZUMAB;

ABDOMINAL BRUIT; ABDOMINAL CLAUDICATION; ABDOMINAL DISEASE; ADULT; AORTA ARCH SYNDROME; ARM CLAUDICATION; ARTHRALGIA; ARTICLE; CASE REPORT; CLAUDICATION; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HEADACHE; HUMAN; MYALGIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; VASCULITIS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPASSIONATE USE TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RECEPTORS, INTERLEUKIN-6; SALVAGE THERAPY; TAKAYASU ARTERITIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WHOLE BODY IMAGING;

EID: 84863756702     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. HOFFMAN GS, MERKEL PA, BRASINGTON RD, LENSCHOW DJ, LIANG P Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004; 50: 2296-304.
2. MOLLOY ES, LANGFORD CA, CLARK TM, GOTA CE, HOFFMAN GS Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008; 67: 1567-9.
3. PARK MC, LEE SW, PARK YB, LEE SK Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford) 2006; 45: 545-8.
4. NORIS M, DAINA E, GAMBA S, BONAZZOLA S, REMUZZI G Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation 1999; 100: 55-60
5. SALVARANI C, CANTINI F, BOIARDI L, HUNDER GG Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis. Clin Exp Rheumatol 2003; 21 (Suppl. 32): S23-8.
6. SEKO Y, SATO O, TAKAGI A et al. Restricted usage of T-cell receptor Valpha-Vbeta genes in infiltrating cells in aortic tissue of patients with Takayasu's arteritis. Circulation 1996; 93: 1788-90.
7. SEITZ M, REICHENBACH S, BONEL HM, ADLER S, WERMELINGER F, VILLIGER PM Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011; 141: w13156.
8. BEYER C, AXMANN R, SAHINBEGOVIC E et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis 2011; 70: 1874-5.
9. NISHIMOTO N, NAKAHARA H, YOSHIOHOSHINO N, MIMA T Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008; 58: 1197-200.
10. MISHRA R, DANDA D, JAYASEELAN L, SIVAKUMAR R, LAWRENCE A, BACON PA ITAS & DEI. TAK scores for clinical disease activity and damage extent in Takayasu's aortoarteritis (TA). Rheumatology (Oxford). 2008; 47.ii:101.
11. KERR GS, HALLAHAN CW, GIORDANO J et al. Takayasu arteritis. Ann Intern Med 1994; 120: 919-29.
12. WALTER MA, MELZER RA, SCHINDLER C, MÜLLER-BRAND J, TYNDALL A, NITZSCHE EU The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging 2005; 32: 674-81.
13. MAKSIMOWICZ-MCKINNON K, HOFFMAN GS Takayasu arteritis: what is the long-term prognosis? Rheum Dis Clin North Am 2007; 33: 777-86
14. SALVARANI C, PIPITONE N Treatment of large-vessel vasculitis: where do we stand? Clin Exp Rheumatol 2011; 29 (Suppl. 64):S3-5.
15. DIRESKENELI H, AYDIN SZ, MERKEL PA Assessment of disease activity and progression in Takayasu's arteritis. Clin Exp Rheumatol 2011; 29 (Suppl. 64): S86-91. 2
16. NISHIMOTO N, TERAO K, MIMA T, NAKAHARA H, TAKAGI N, KAKEHI T Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112: 3959-64.
17. UCHIYAMA Y, YOSHIDA H, KOIKE N et al. Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production. Int Immunopharmacol 2008; 8: 1595-601.